Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Am J Respir Crit Care Med

Retrieve available abstracts of 120 articles:
HTML format



Single Articles


    April 2021

  1. Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    


  2. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    


    March 2021
  3. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available


  4. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available


  5. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    


  6. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    


  7. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    


    February 2021
  8. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    


    January 2021
  9. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available


  10. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available


    December 2020
  11. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    


    November 2020
  12. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available


    September 2020

  13. Erratum: Lower Bacillus Calmette-Guerin Protection against Mycobacterium tuberculosis Infection after Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020;202:909-910.
    PubMed    


  14. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    


  15. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    


    August 2020
  16. BURZYNSKI J, Keshavjee S
    Supporting a Comprehensive, International Approach to Global Tuberculosis Eradication is the Right Thing to Do.
    Am J Respir Crit Care Med. 2020 Aug 24. doi: 10.1164/rccm.202007-2976.
    PubMed    


  17. O'DONNELL M, Mathema B
    Operational Research on the Treatment of Drug-resistant Tuberculosis: Exciting Results that Need to be Protected.
    Am J Respir Crit Care Med. 2020 Aug 21. doi: 10.1164/rccm.202007-2974.
    PubMed    


  18. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    


    July 2020
  19. SCHLUGER NW
    Prevention of Multidrug-resistant Tuberculosis in Close Contacts: Back to the Future?
    Am J Respir Crit Care Med. 2020 Jul 27. doi: 10.1164/rccm.202006-2488.
    PubMed    


  20. MENZIES NA, Bellerose M, Testa C, Swartwood N, et al
    Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.
    Am J Respir Crit Care Med. 2020 Jul 9. doi: 10.1164/rccm.202003-0526.
    PubMed     Abstract available


  21. PODANY AT
    Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
    Am J Respir Crit Care Med. 2020 Jul 7. doi: 10.1164/rccm.202006-2144.
    PubMed    


  22. CUTLER T, Scales D, Levine W, Schluger N, et al
    A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jul 1. doi: 10.1164/rccm.202003-0828.
    PubMed    


    June 2020
  23. RODRIGUEZ CA, Sy KTL, Mitnick CD, Franke MF, et al
    Time Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias.
    Am J Respir Crit Care Med. 2020 Jun 18. doi: 10.1164/rccm.202001-0220.
    PubMed    


  24. HUANG CC, Becerra MC, Calderon R, Contreras C, et al
    Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jun 17. doi: 10.1164/rccm.201908-1576.
    PubMed     Abstract available



  25. Erratum: Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2020;201:1454.
    PubMed    


  26. JAIN S, Kumar P, Goyal JP
    Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452.
    PubMed    


  27. ZAR HJ
    Reply to Jain et al.: Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452-1453.
    PubMed    


    May 2020
  28. SCHEUERMANN L, Pei G, Domaszewska T, Zyla J, et al
    Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis.
    Am J Respir Crit Care Med. 2020 May 18. doi: 10.1164/rccm.201910-2063.
    PubMed     Abstract available


  29. HIBMA JE, Radtke KK, Dorman SE, Jindani A, et al
    Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489.
    PubMed     Abstract available


  30. DAVIDS M, Pooran A, Hermann C, Mottay L, et al
    A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guerin.
    Am J Respir Crit Care Med. 2020;201:1277-1291.
    PubMed     Abstract available


    April 2020
  31. DHEDA K, Davids M
    Latent Tuberculosis Infection-associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?
    Am J Respir Crit Care Med. 2020;201:895-898.
    PubMed    


  32. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0855.
    PubMed    


  33. SWINDELLS S, Hughes M, Chaisson RE
    Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0761.
    PubMed    


    March 2020
  34. DOOLEY KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al
    Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
    PubMed    


  35. DECROO T, de Jong BC, Piubello A, Souleymane MB, et al
    High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202001-0201.
    PubMed    


    February 2020
  36. WASSERMAN S, Furin J
    Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
    Am J Respir Crit Care Med. 2020 Feb 20. doi: 10.1164/rccm.202002-0264.
    PubMed    



  37. Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2020;201:500-501.
    PubMed    


  38. VERNON A, Bishai W
    Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
    Am J Respir Crit Care Med. 2020;201:405-406.
    PubMed    


  39. ANDRES S, Merker M, Heyckendorf J, Kalsdorf B, et al
    Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon.
    Am J Respir Crit Care Med. 2020 Feb 13. doi: 10.1164/rccm.201909-1819.
    PubMed    


    January 2020
  40. DE JAGER VR, Vanker N, van der Merwe L, van Brakel E, et al
    Optimising beta-lactams Against Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149.
    PubMed    


  41. VERRALL AJ, Chaidir L, Ruesen C, Apriani L, et al
    Lower BCG Protection Against Mycobacterium tuberculosis Infection After Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020 Jan 8. doi: 10.1164/rccm.201912-2349.
    PubMed    


  42. MCSHANE H
    Controlled Human Infection Models - Is it Really Feasible to Give People Tuberculosis?
    Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2408.
    PubMed    


    December 2019
  43. GUPTA RK, Lipman M, Jackson C, Sitch A, et al
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0969.
    PubMed     Abstract available


  44. ABUBAKAR I, Cobelens FG, Rangaka MX
    The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.
    Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258.
    PubMed    


    November 2019
  45. NISHIZAWA S, Tobino K
    Asymptomatic Tuberculous Pleurisy Mimicking Mesothelioma.
    Am J Respir Crit Care Med. 2019 Nov 25. doi: 10.1164/rccm.201906-1223.
    PubMed    


  46. NAHID P, Mase SR, Migliori GB, Sotgiu G, et al
    Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2019;200:e93-e142.
    PubMed     Abstract available


  47. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed    


  48. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606.
    PubMed     Abstract available


  49. NARITA M, Sullivan Meissner J, Burzynski J
    Use of Modeling to Inform Tuberculosis Elimination Strategies.
    Am J Respir Crit Care Med. 2019 Nov 7. doi: 10.1164/rccm.201910-2061.
    PubMed    


    October 2019
  50. TEZERA LB, Mansour S, Elkington P
    Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.
    Am J Respir Crit Care Med. 2019 Oct 28. doi: 10.1164/rccm.201908-1506.
    PubMed     Abstract available


  51. FOREMAN TW, Bucsan AN, Mehra S, Peloquin C, et al
    Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2019 Oct 24. doi: 10.1164/rccm.201903-0646.
    PubMed     Abstract available


  52. MENZIES NA, Parriott A, Shrestha S, Dowdy DW, et al
    Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289.
    PubMed     Abstract available


  53. AUBRY A, Veziris N
    Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1072-1073.
    PubMed    


  54. CHOI HW, Shin JH, Kee SJ, Kwon YS, et al
    Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1073-1074.
    PubMed    


    September 2019
  55. SAGAR AS, Dodge DL, Salahuddin M, Warner MT, et al
    Pleural Diseases: Pleurodesis via Indwelling Pleural Catheter, Dasatinib-induced Pleural Effusion, and IL-27 in Tuberculosis Pleural Effusion.
    Am J Respir Crit Care Med. 2019;200:771-773.
    PubMed    


    August 2019
  56. SCHAAF HS, Marais BJ
    The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children.
    Am J Respir Crit Care Med. 2019 Aug 6. doi: 10.1164/rccm.201907-1492.
    PubMed    


  57. ZAR HJ, Workman LJ, Prins M, Bateman LJ, et al
    Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2019 Aug 5. doi: 10.1164/rccm.201904-0772.
    PubMed     Abstract available


    May 2019
  58. NIEDERMAN MS, Nair GB, Matt U, Herold S, et al
    Update in Lung Infections and Tuberculosis 2018.
    Am J Respir Crit Care Med. 2019 May 1. doi: 10.1164/rccm.201903-0606.
    PubMed    


    April 2019
  59. KRANZER K, Kalsdorf B, Heyckendorf J, Andres S, et al
    New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Am J Respir Crit Care Med. 2019 Apr 26. doi: 10.1164/rccm.201902-0260.
    PubMed    


    March 2019
  60. LEE HS, Kee SJ, Shin JH, Kwon YS, et al
    Xpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting.
    Am J Respir Crit Care Med. 2019;199:784-794.
    PubMed     Abstract available


  61. YOON C, Semitala FC, Cattamanchi A
    Reply to Parker: Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:665.
    PubMed    


  62. PARKER RA
    Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:664.
    PubMed    


    February 2019
  63. GUPTA S, Krug S, Pokkali S, Leanderson T, et al
    Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
    Am J Respir Crit Care Med. 2019;199:386-389.
    PubMed    


    January 2019
  64. DHEDA K, Lenders L, Srivastava S, Magombedze G, et al
    Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.
    Am J Respir Crit Care Med. 2019 Jan 29. doi: 10.1164/rccm.201807-1361.
    PubMed     Abstract available


  65. TE BRAKE LHM, Boeree MJ, Aarnoutse RE
    Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201811-2101.
    PubMed    


  66. VELASQUEZ GE, Brooks MB, Coit JM, Sanchez Garavito E, et al
    Reply to: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201812-2281.
    PubMed    


  67. SULIMAN S, Luabeya AKK, Geldenhuys H, Tameris M, et al
    Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Am J Respir Crit Care Med. 2019;199:220-231.
    PubMed     Abstract available


    October 2018
  68. SCHLUGER NW
    Tuberculosis Elimination, Research, and Respect for Persons.
    Am J Respir Crit Care Med. 2018 Oct 19. doi: 10.1164/rccm.201809-1623.
    PubMed    


  69. KESHAVJEE S, Amanullah F, Cattamanchi A, Chaisson R, et al
    Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2018 Oct 18. doi: 10.1164/rccm.201806-1053.
    PubMed     Abstract available


  70. MARTINEZ L, Andrews JR
    Improving Tuberculosis Case Finding in Persons Living with Advanced HIV through New Diagnostic Algorithms.
    Am J Respir Crit Care Med. 2018 Oct 1. doi: 10.1164/rccm.201809-1702.
    PubMed    


    September 2018
  71. YOON C, Semitala FC, Asege L, Katende J, et al
    Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV.
    Am J Respir Crit Care Med. 2018 Sep 7. doi: 10.1164/rccm.201803-0490.
    PubMed     Abstract available


    August 2018
  72. ELKINGTON PT, Bateman AC, Thomas GJ, Ottensmeier CH, et al
    Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
    Am J Respir Crit Care Med. 2018 Aug 24. doi: 10.1164/rccm.201807-1250.
    PubMed    


    June 2018
  73. VELASQUEZ GE, Brooks MB, Coit JM, Pertinez H, et al
    Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2018 Jun 29. doi: 10.1164/rccm.201712-2524.
    PubMed     Abstract available


  74. DHEDA K, Lenders L, Magombedze G, Srivastava S, et al
    Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients.
    Am J Respir Crit Care Med. 2018 Jun 7. doi: 10.1164/rccm.201711-2333.
    PubMed     Abstract available


    April 2018
  75. MONEDERO-RECUERO I
    Drug-resistant Tuberculosis in Europe. What are We Waiting for?
    Am J Respir Crit Care Med. 2018 Apr 18. doi: 10.1164/rccm.201803-0497.
    PubMed    


  76. SULIMAN S, Thompson E, Sutherland J, Weiner Rd J, et al
    Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
    Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340.
    PubMed     Abstract available


    March 2018
  77. ABUBAKAR I, Gupta RK, Rangaka MX, Lipman M, et al
    Update in Tuberculosis and Non-tuberculous Mycobacteria 2017.
    Am J Respir Crit Care Med. 2018 Mar 14. doi: 10.1164/rccm.201801-0106.
    PubMed    


  78. COX D, Keane J
    Platelets and Tuberculosis: Small Cells, Not So Innocent Bystanders.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201802-0279.
    PubMed    


  79. GUNTHER G, van Leth F, Alexandru S, Altet N, et al
    Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201710-2141.
    PubMed     Abstract available


    February 2018
  80. SCHWANDER S, Keane J
    Cause or Effect - the Elusive Role of Regulatory T Cells in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 28. doi: 10.1164/rccm.201802-0233.
    PubMed    


  81. FOX KA, Kirwan DE, Whittington AM, Krishnan N, et al
    Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 8. doi: 10.1164/rccm.201710-2102.
    PubMed     Abstract available


    December 2017
  82. ERNST JD
    Float Like Bacilli, STING Like a B: Type I Interferons in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Dec 20. doi: 10.1164/rccm.201712-2368.
    PubMed    


  83. VARAINE F, Guglielmetti L, Mitnick CD
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1490-1491.
    PubMed    


  84. VAN LETH F, Gunther G, Hoffmann H, Lange C, et al
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1489-1490.
    PubMed    


  85. BARRY PM, Lowenthal P, True L, Henry L, et al
    Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1488-1489.
    PubMed    


    November 2017
  86. BENARD A, Sakwa I, Schierloh P, Colom A, et al
    B Cells Producing Type I Interferon Modulate Macrophage Polarization in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Nov 21. doi: 10.1164/rccm.201707-1475.
    PubMed     Abstract available


    October 2017
  87. DIVANGAHI M, Behr MA
    Cracking the Vaccine Code in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Oct 18. doi: 10.1164/rccm.201707-1489.
    PubMed     Abstract available


  88. MARTINEZ L, Handel A, Shen Y, Chakraburty S, et al
    A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts.
    Am J Respir Crit Care Med. 2017 Oct 16. doi: 10.1164/rccm.201706-1210.
    PubMed    


  89. DHEDA K
    The Multistep Tuberculosis Diagnostic Cascade. More Than Meets the Eye.
    Am J Respir Crit Care Med. 2017;196:809-811.
    PubMed    


    September 2017
  90. ROSSER A, Pareek M, Turapov O, Wiselka MJ, et al
    Differentially Culturable Tubercule Bacilli are Generated During Non-pulmonary Tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Sep 7. doi: 10.1164/rccm.201705-1048.
    PubMed    


    August 2017
  91. LEWINSOHN D
    An Expanding Role for Environmental Microbes in Shaping the Immune Response to Infection with Mycobacterium Tuberculosis.
    Am J Respir Crit Care Med. 2017 Aug 25. doi: 10.1164/rccm.201708-1599.
    PubMed    


  92. BANAEI N, Pai M
    Detecting New Mycobacterium Tuberculosis Infection: Time for a More Nuanced Interpretation of QuantiFERON Conversions.
    Am J Respir Crit Care Med. 2017 Aug 1. doi: 10.1164/rccm.201707-1543.
    PubMed    


    July 2017
  93. ABUBAKAR I, Kloprogge F
    End of the Road for Adjunctive Vitamin D Therapy for Pulmonary Tuberculosis?
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201707-1509.
    PubMed    


  94. SCRIBA TJ, Carpenter C, Carrasco Pro S, Sidney J, et al
    Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History.
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201706-1208.
    PubMed     Abstract available


  95. CLAYTON K, Polak ME, Woelk CH, Elkington P, et al
    Gene Expression Signatures in Tuberculosis Have Greater Overlap with Autoimmune Than Infectious Diseases.
    Am J Respir Crit Care Med. 2017 Jul 28. doi: 10.1164/rccm.201706-1248.
    PubMed    


  96. NEMES E, Rozot V, Geldenhuys H, Bilek N, et al
    Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of M. tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Jul 24. doi: 10.1164/rccm.201704-0817.
    PubMed     Abstract available


  97. LESSELLS RJ, Cooke GS, McGrath N, Nicol MP, et al
    Impact of Point-of-care Xpert MTB/RIF on Tuberculosis Treatment Initiation: A Cluster Randomised Trial.
    Am J Respir Crit Care Med. 2017 Jul 20. doi: 10.1164/rccm.201702-0278.
    PubMed     Abstract available


  98. GANMAA D, Munkhzul B, Fawzi W, Spiegelman D, et al
    High-Dose Vitamin D3 During Tuberculosis Treatment in Mongolia: A Randomised Controlled Trial.
    Am J Respir Crit Care Med. 2017 Jul 10. doi: 10.1164/rccm.201705-0936.
    PubMed     Abstract available


    June 2017
  99. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Cryptic Micro-heteroresistance Explains M. tuberculosis Phenotypic Resistance.
    Am J Respir Crit Care Med. 2017 Jun 14. doi: 10.1164/rccm.201703-0556.
    PubMed     Abstract available


  100. BURZYNSKI J
    The Use of Modeling to Compare Tuberculosis Dynamics in Four US States.
    Am J Respir Crit Care Med. 2017 Jun 13. doi: 10.1164/rccm.201705-0963.
    PubMed    


  101. GRANDJEAN L
    Investigating the Pathogen Genomic Determinants of Tuberculosis Transmission.
    Am J Respir Crit Care Med. 2017;195:1418-1420.
    PubMed    



  102. Erratum: New Guidelines for the Treatment of Drug-Susceptible Tuberculosis from the American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America: Now Comes the Hard Part.
    Am J Respir Crit Care Med. 2017;195:1540.
    PubMed    


    May 2017
  103. SHRESTHA S, Hill AN, Marks SM, Dowdy DW, et al
    Comparing Drivers and Dynamics of Tuberculosis (TB) in California, Florida, New York and Texas.
    Am J Respir Crit Care Med. 2017 May 5. doi: 10.1164/rccm.201702-0377.
    PubMed     Abstract available


  104. SHAH JA, Musvosvi M, Shey M, Horne DJ, et al
    A Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses and Tuberculosis.
    Am J Respir Crit Care Med. 2017 May 2. doi: 10.1164/rccm.201611-2346.
    PubMed     Abstract available


  105. SCHLUGER NW
    AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.
    Am J Respir Crit Care Med. 2017;195:1112-1114.
    PubMed    


  106. ALLINSON JP, Mackay AJ, Shah PL
    AJRCCM: 100-Year Anniversary. Special Historical Image Section: Tuberculosis Then and Now.
    Am J Respir Crit Care Med. 2017;195:1118-1123.
    PubMed    


  107. VAN ZYL-SMIT RN, Esmail A, Bateman ME, Dawson R, et al
    Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
    Am J Respir Crit Care Med. 2017;195:1171-1180.
    PubMed     Abstract available


  108. WEDZICHA JA, Brochard LJ, Martinez FD, Martinez FJ, et al
    AJRCCM: 100-Year Anniversary. The Long View and the Fast Lane.
    Am J Respir Crit Care Med. 2017;195:1081-1085.
    PubMed    


  109. SAEKI K, Watanabe S, Waseda Y, Kasahara K, et al
    Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient.
    Am J Respir Crit Care Med. 2017;195:e37-e38.
    PubMed    


    April 2017
  110. DIACON AH, van Brakel E, Lounis N, Meyvisch P, et al
    Triplicate Sputum Cultures for Efficacy Evaluation of Novel Anti-tuberculosis Regimens.
    Am J Respir Crit Care Med. 2017 Apr 27. doi: 10.1164/rccm.201704-0796.
    PubMed    


    March 2017
  111. DEDICOAT MJ, Gunther G, Crudu V, Duarte R, et al
    Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585.
    PubMed    


  112. STOUT JE, Dicks KV
    A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection.
    Am J Respir Crit Care Med. 2017;195:716-717.
    PubMed    


    February 2017

  113. What is Tuberculosis (TB)?
    Am J Respir Crit Care Med. 2017;195:P7-P8.
    PubMed    


    December 2016
  114. NEBENZAHL-GUIMARAES H, van Laarhoven A, Farhat MR, Koeken VA, et al
    Transmissible Mycobacterium tuberculosis Strains Share Genetic Markers and Immune Phenotypes.
    Am J Respir Crit Care Med. 2016 Dec 20. doi: 10.1164/rccm.201605-1042.
    PubMed     Abstract available


  115. DARTOIS V, Saito K, Warrier T, Nathan C, et al
    New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges.
    Am J Respir Crit Care Med. 2016;194:1448-1451.
    PubMed    


    November 2016
  116. LEU JS, Chen ML, Chang SY, Yu SL, et al
    SP110b Controls Host Immunity and Susceptibility to Tuberculosis.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available


  117. HARAUSZ EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, et al
    New/Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis: Practice-Based Recommendations.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available


  118. GUGLIELMETTI L, Le Du D, Frechet-Jachym M, Mitnick C, et al
    Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.
    Am J Respir Crit Care Med. 2016;194:1170-1171.
    PubMed    


  119. SAUNDERS MJ, Datta S
    Contact Investigation: A Priority for Tuberculosis Control Programs.
    Am J Respir Crit Care Med. 2016;194:1049-1051.
    PubMed    


    October 2016
  120. VARAINE F, Guglielmetti L, Huerga H, Bonnet M, et al
    Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Am J Respir Crit Care Med. 2016;194:1028-1029.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: